Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes

OBJECTIVE Interleukin (IL)-1 impairs insulin secretion and induces β-cell apoptosis. Pancreatic β-cell IL-1 expression is increased and interleukin-1 receptor antagonist (IL-1Ra) expression reduced in patients with type 2 diabetes. Treatment with recombinant IL-1Ra improves glycemia and β-cell function and reduces inflammatory markers in patients with type 2 diabetes. Here we investigated the durability of these responses. RESEARCH DESIGN AND METHODS Among 70 ambulatory patients who had type 2 diabetes, A1C >7.5%, and BMI >27 kg/m2 and were randomly assigned to receive 13 weeks of anakinra, a recombinant human IL-1Ra, or placebo, 67 completed treatment and were included in this double-blind 39-week follow-up study. Primary outcome was change in β-cell function after anakinra withdrawal. Analysis was done by intention to treat. RESULTS Thirty-nine weeks after anakinra withdrawal, the proinsulin-to-insulin (PI/I) ratio but not stimulated C-peptide remained improved (by −0.07 [95% CI −0.14 to −0.02], P = 0.011) compared with values in placebo-treated patients. Interestingly, a subgroup characterized by genetically determined low baseline IL-1Ra serum levels maintained the improved stimulated C-peptide obtained by 13 weeks of IL-1Ra treatment. Reductions in C-reactive protein (−3.2 mg/l [−6.2 to −1.1], P = 0.014) and in IL-6 (−1.4 ng/l [−2.6 to −0.3], P = 0.036) were maintained until the end of study. CONCLUSIONS IL-1 blockade with anakinra induces improvement of the PI/I ratio and markers of systemic inflammation lasting 39 weeks after treatment withdrawal.

[1]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[2]  Eric J. Brunner,et al.  Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes , 2009, Diabetes Care.

[3]  P. Halban,et al.  Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. , 2008, The Journal of clinical endocrinology and metabolism.

[4]  Jackie A Cooper,et al.  Inflammation, Insulin Resistance, and Diabetes—Mendelian Randomization Using CRP Haplotypes Points Upstream , 2008, PLoS medicine.

[5]  C. Desmarais,et al.  Polymorphisms of the IL1-Receptor Antagonist Gene (IL1RN) Are Associated With Multiple Markers of Systemic Inflammation , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[6]  H. Tian,et al.  Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial , 2008, The Lancet.

[7]  G. Sundkvist,et al.  Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4‐year follow‐up , 2008, Diabetes, obesity & metabolism.

[8]  H. Ellingsgaard,et al.  Increased Number of Islet-Associated Macrophages in Type 2 Diabetes , 2007, Diabetes.

[9]  S. Bandinelli,et al.  Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels , 2007, Genes and Immunity.

[10]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[11]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[12]  C. Ohlsson,et al.  Interleukin-1 system gene polymorphisms are associated with fat mass in young men. , 2006, The Journal of clinical endocrinology and metabolism.

[13]  H. Kolb,et al.  An immune origin of type 2 diabetes? , 2005, Diabetologia.

[14]  J. Levy,et al.  Use and abuse of HOMA modeling. , 2004, Diabetes care.

[15]  P. Halban,et al.  Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Robert A. Rizza,et al.  β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.

[17]  O. Wagner,et al.  Interleukin-1 receptor antagonist genotype is associated with coronary atherosclerosis in patients with type 2 diabetes. , 2002, Diabetes.

[18]  M. Hurme,et al.  IL‐1 receptor antagonist (IL‐1Ra) plasma levels are co‐ordinately regulated by both IL‐1Ra and IL‐1β genes , 1998 .

[19]  T. Mandrup-Poulsen,et al.  The role of interleukin-1 in the pathogenesis of IDDM , 1996, Diabetologia.

[20]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[21]  E. Cerasi Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? , 1995, Diabetologia.

[22]  F. Pociot,et al.  Monokine Antagonism Is Reduced in Patients With IDDM , 1994, Diabetes.

[23]  J. Nerup,et al.  Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. , 1986, Science.

[24]  P. Zimmet,et al.  Diagnosis and classification of diabetes mellitus , 2002 .

[25]  V. Pascual,et al.  Gene expression in peripheral blood mononuclear cells from children with diabetes. , 2007, The Journal of clinical endocrinology and metabolism.